This market report provides a comprehensive and easy-to-review analysis of the immunoassay market 2016 to 2020, providing key market data and identifying new and emerging opportunities across this field. This analysis is based on primary data disclosed by experienced end-users on their current immunoassay practices and their plans over the next three years. Its findings provide a wealth of market information on immunoassay and enable suppliers to target new markets and reduce costs.
More than 50 companies are mentioned in this report and these include Abbott Laboratories, Abcam, AccuBioTech, BD, Beckman Coulter, Berthold, Biohit, Biomerica, Biomerieux, Bio-Rad, Biotek, Biotron Diagnostics, BMG Labtech, Core Life Sciences, Diasorin, Dynex, Euroimmun, Fisher Scientific, GE Healthcare, Hema Diagnostic Systems, Idexx, Isogen Life Sciences Immunodiagnostics, Life Technologies, Luminex Corp, Molecular Devices, Molecular Diagnostics, Operon, Perkin Elmer, Pointe Scientific, Pro-Lab Diagnostics, Qiagen, Quanterix Corp, R-Biopharm AG, Roche Diagnostics, Samsung, Siemens, Tecan and Thermo Fisher and others.
Biopharm Reports' specialised market studies are designed to assist suppliers and developers to profile current and evolving laboratory market opportunities. All of our studies are carried out through specialist groups of experienced end-users and therefore findings are based on 'real world' market data. By providing new insights and a better understanding of end-user practices, needs and future plans, our studies assist suppliers to sell into these markets, and also support innovation and strategic planning. The following study areas were investigated:
Based on recent trends in the numbers of samples analysed in their laboratories using immunoassay, end-user's own estimates of by how much (% increase or % decrease) their laboratory use of immunoassay has changed over the last three years. Also, based on current trends in the numbers of samples analysed in their laboratories, end-user's own estimates of by how much (% increase or % decrease) they anticipate their laboratory use of immunoassay will change over the next three years.
Immunoassay Instrument Suppliers ++
Immunoassay Instruments (by Model Number)
Clinical & Research Use: End-users' current main immunoassay instruments (i.e. readers) and those immunoassay instruments (readers) they anticipate using in their laboratories in three years from now, where the instruments considered were Abbott Laboratories-ARCHITECT ci16200,Abbott Laboratories-ARCHITECT ci4100,Abbott Laboratories-ARCHITECT ci8200,Abbott Laboratories-ARCHITECT i1000SR,Abbott Laboratories-ARCHITECT i2000SR,Abbott Laboratories-ARCHITECT i4000SR,Abcam-Dipstick Reader,AccuBioTech-Elisa Reader (ABER-2),AESKU DIAGNOSTICS-HELIA,Alverix (BD)-BD Veritor,AmniSure (Qiagen)-Rapid Reader,Autobio Diagnostics-PHOmo,Awareness Tech-ChemWell® 2910,BD-BD Veritor,Beckman Coulter-Access 2,Beckman Coulter-UniCel DxC 660i,Beckman Coulter-UniCel® DxC 860i,Beckman Coulter-UniCel® DxI 600,Beckman Coulter-UniCel® DxI 800,Berthold-Apollo 11 LB 913,Berthold-Artemis K-101,Berthold-Centro LB 960,Berthold-CentroPRO LB 962,Berthold-Mithras LB 940,Berthold-TriStar2 LB 942,Biokit (Werfen Group)-BIO-FLASH,Biomerieux-Mini Vidas,Biomerieux-Vidas,Bio-Rad Laboratories-Elite,Bio-Rad Laboratories-PhD Ix System,Bio-Rad Laboratories-PR4100,Bioscience Diag Tech-Peteck96-1,Biosensia-RapiPlex,BioTek Instruments-Cytation 5,BioTek Instruments-ELx800,Biotek-Cytation 3,Biotek-Synergy 2,Biotek-Synergy H1,Biotek-Synergy H4,Biotek-Synergy NEO,BMG Labtech-CLARIOstar,BMG Labtech-FLUOstar,BMG Labtech-LUMIstar,BMG LABTECH-PHERAstar,BMG Labtech-POLARstar,BMG Labtech-SPECTROstar,BMG-NEPHELOstar Plus,BMG-PHERAstar Nano,Boditech Med Inc.-ichroma,CardioGenics Holdings-QL Care,Clearbridge BioLoc-AssayQuest,Core Life Sciences-PHOmo,Corgenix Medical-SkyLAB752,DIALAB-Autolyser 450,Diamedix Corp-Diamedix MAGO,Diasorin-ETI-MAX 3000,Diasorin-LAISON XL,DIAsource Immuno Assays-DIAspot Reader,DIAsource ImmunoAssays-Neptune,DiaSys Diagnostic Systems-StarDust MC15,DIESSE Diagnostica Senese-Seramat,DRG International-HYBRiD-XL,D-tek-BlueDiver,Dynex Technologies-Agility,Dynex Technologies-DSX,Dynex Technologies-Dynex DS2,Epocal-Epoc,ERBA Diagnostics-Dynex DS2,ERBA-Erba Lisa Scan EM,ERBA-Erba Lisa Scan II,ERBA-Mago 4,Euroimmun-IF Sprinter,Fisher Scientific-Diamedix MAGO,GeneFluidics-Proteus Robotic,Getein Biotech-GP FIA8000,Gold Standard Diagnostics Corp-ThunderBolt,Hidex-Sense,HYCOR Biomedical-HYTEC 288 Plus,IDS-IDS-iSYS,Immunodiagnostics-IDS-iSYS,Innova Diagnostics-BIO-FLASH,INOVA Diagnostics-Best 2000,INOVA Diagnostics-BIO-FLASH,INOVA Diagnostics-DSX,INOVA Diagnostics-Dynex DS2,INOVA Diagnostics-Quanta Lyser 2,INOVA Diagnostics-Quanta Lyser 240,International Immuno-Diagnostics-Manual EIA Reader,International Immuno-Diagnostics-Stat Fax 2100,International Immuno-Diagnostics-TKA 310,International Immuno-Diagnostics-TKA 500 Line,Isogen Life Sciences-LUMIstar Omega,Jei Daniel Biotech Corp.-Immuno Gold Reader,LabLogic-Hidex Sense,MBio Diagnostics-LightDeck,Molecular Devices-EMax Plus,Molecular Devices-FlexStation 3,Molecular devices-Spectramax i3,Molecular devices-Spectramax M5e,Molecular devices-Spectramax PARADIGM,Molecular Devices-VMax Kinetic,Molecular Diagnostics-VersaMax,OPKU Health-The Claros analyzer,Ortho Clinical-ORTHO VISION,Ortho Clinical-VITROS 3600,Ortho Clinical-VITROS Eci,Perfemed Group-Elisa Microplate,Pointe Scientific-Pointe 180 SR,Princeton Biomeditech-DXpress Reader,Qualigen-The FastPack IP System,Quanterix Corp-Simoa HD-1 analyzer,Radiometer Medical ApS-AQT90 FLEX,Randox-Evidence Evolution,Randox-Evidence Investigator,Roche Diagnostics-Cobas 411,Roche Diagnostics-cobas 6000,Roche Diagnostics-Cobas 601,Roche Diagnostics-Cobas 602,Roche Diagnostics-cobas 8000,Roche Diagnostics-cobas e411,Siemens Healthcare:-ADVIA Centaur CP,Siemens Healthcare:-ADVIA Centaur XP,Siemens Healthcare:-ADVIA Centaur XPT,Siemens Healthcare:-Dimension EXL 200,Siemens Healthcare:-Dimension Vista 1500,Siemens Healthcare:-Dimension Vista 500,Siemens Healthcare:-Immulite 2000 Xpi,Siemens-Dimension Xpand Plus,Siemens-Dimention EXL,Siemens-Dimention RxL Max,Siemens-Dimention Vista 1500,Siemens-Dimention Vista 3000T,Siemens-Immulite 1000,Siemens-Immulite 2000,SQi Diagnostics-Sqidlite,SQi Diagnostics-Sqidworks,SQi Diagnostics-Sqid-X,Tecan-Infinite 200 PRO NanoQuant,Tecan-Infinite F200 PRO,Tecan-Infinite F50,Tecan-Infinite F500,Tecan-Infinite M1000 PRO,Tecan-Infinite M200,Tecan-Spark 10M,Tecan-Sunrise,Theradiag-CARIS,Theradiag-Chorus,Theradiag-FIDIS, Theradiag-Theralis µ,Theradiag-Theralis,Thermo Fisher-Fluoroskan Ascent,Thermo Fisher-Luminoskan Ascent,Thermo Fisher-Multiskan,Thermo Fisher-Phadia System 100,Thermo Fisher-Phadia System 1000,Thermo Fisher-Phadia System 250,Thermo Fisher-Phadia System 2500, Thermo Fisher-Phadia System 5000,Thermo Fisher-Varioskan Flash,Thermo Fisher-Varioskan LUX,Tosoh Corp-AIA-1800,Tosoh Corp-AIA-2000,Tosoh Corp-AIA-360,Tosoh Corp-AIA-600 II,Tosoh Corp-AIA-900,Transasia Bio-Medicals-Elan 30 s,Transasia Bio-Medicals-Erba Lisa Scan EM,Transasia Bio-Medicals-Erba Lisa Scan II,Transasia Bio-Medicals-Mago 4,VEDA.LAB-EASY READER 36100,Vircell S.L.-Dynex DS2 or any others.
Immunoassay Consumables Suppliers ++
++ This listing of suppliers may include companies that have been acquired by other companies, changed their names, or moved out of this field and transferred their products to a third party. This is because, in our experience, end-users often refer to original supplier's and product names, even when companies have been acquired, changed their company name, or where a product range is made available through an alternative third party
Market Size (Study Group)
Clinical & Research Use: End-users' current main immunoassay applications used in their laboratories and those immunoassy applications they anticipate they will be using in their laboratories in three years from now, where the applications considered were Alcohol screening, Allergy, Anemia, Antiphospholipid Syndrome (APS), Autoimmune, Blood Borne, Blood Genotyping, Bone, Brain damages, Breast Care, Cancer markers, Cardiac, Cardiometabolic, Cardiovascular, Cartilage, Celiac Disease, Circulating Immuno Complexes, Coagulation, Complement, Connective Tissue, Critical Care, Diabetes, Drug Abuse Tests, Endocrinology, Fertility, FOB Tests, Food Intolerance, Gastrointestinal, Genetic, Growth Factors, Hepatitis, Hormones, Hypertension, Immunology Markers, Infections – Bacterial, Infections – Viral, Inflammation, Liver Disease, Metabolism, Misfolded Proteins, Neurodegenerative diseases, Neuroscience, Newborn screening, Obesity, Ovulation, Perinatal, Pregnancy, Primary Immunodeficiency (PID), Rheumatoid Arthritis, Saliva Drug Screens, Sepsis, Sexually Transmitted, Smoking, Thrombosis/Coagulation, Thyroid Diseases, Toxicology, Tropic al Diseases, Urine Tests, Vascular disease, Vasculitis, Veterinary, Vitamin deficiencies, Women's Health and any others.
Multimplexing of Immunoassay
Clinical & Research Use: End-users' current levels of multiplexing of immunoassay and the levels of multiplexing of immunoassy they anticipate they will be using in their laboratories in three years from now, where the multiplexing levels considerted were 1 to 5, 6 to 10, 15/11/2015 00:00:00, 16-20, 21-30, 31-40, 41-50, 51-60, 61-70, 71-80, 81-90, 91-100, 101-150, 151 – 200, > 200 and No Multiplex Assays.
Clinical & Research Use: End-users' current main immunoassay types used in their laboratories and those immunoassy types they anticipate they will be using in their laboratories in three years from now, where the immunoassay types considered were ELISA – Enzyme Linked ImmunoSorbent Assay, RIA – Radio-ImmunoAssay, EMIT – Enzyme Multiplied Immunoassay, FRET – Fluorescent Resonance Energy Transfer, FPIA – Fluorescent Polarized Immunoassay, KIMS – Kinetic Interaction of Microparticles in Solution, CEDIA – Cloned Enzyme Donor Immunoassay, Lateral Flow Immunoassay and any others.
Clinical & Research Use: End-users' current main immunoassay formats used in their laboratories and those immunoassy formats they anticipate they will be using in their laboratories in three years from now, where the immunoassay formats considered were Competitive, homogeneous immunoassay; Competitive, heterogeneous immunoassay; One-site, noncompetitive immunoassay and Two-site, noncompetitive immunoassay and any others.
Clinical & Research Use: End-users' current main immunoassay labels used in their laboratories and those immunoassy labels they anticipate they will be using in their laboratories in three years from now, where the immunoassay labels considered were Enzymes, Radioactive isotopes, DNA reporters, Fluorogenic reporters, Electrochemiluminescent tags, Labeless immunoassays and any others.
Innovation and Development Needs
End user's estimates of the average costs of their immunoassay analyses for a typical study sample in their laboratory, where the cost levels considered were <$5, $5 - $10, $10 - $20, $20 - $30, $30 - $40, $40 - $50, $50 - $70, $70 - $100, $100 - $150, $150 - $250, $250 - $400, $400 - $600, $600 - $1000 and > $1000.
End user's estimates of the average number of study samples they analyse each month using immunoassay in their laboratory, where the throughput levels considered were <10, 10 - 20, 20 – 30, 30 – 40, 40 – 50, 50 – 70, 70 – 100, 100 – 150, 150 – 250, 250- 400, 400 – 600, 600 – 1000, 1000 – 1500, 1500 – 2000, 2000 – 2500 and > 2500.
Relative Assay Cost Areas
Clinical & Research: In terms of relative costs, end-users own estimates (on a scale of 1 - 7) of the different relative cost levels associated with their immunoassay consumables, where 1 is the lowest relative cost and 7 in the highest and where the options evaluated were Immunoassay kits and reagents,
External services costs,
Instrument service (maintenance) contracts,
Plasticware (tips, tubes etc),
Sample preparation (extraction) kits and reagents,
Software licenses and any other.
End-users' current main fields of use of immunoassay, where the fields considered were Biochemistry, Biology, Biotechnology, Clinical Therapeutics, Clinical Diagnostics, Environmental, Food & Drink, Forensics, Government, Healthcare, Medicine, Natural Products, Pharmaceuticals, Veterinary and any other.
Broad Applications of Immunoassay
End-users current main broad applications of their immunoassay and those main broad applications they anticipate in three years from now, where the broad applications considered were Clinical Therapeutics – Treatment Decisions; Clinical Therapeutics – Treatment Monitoring; Clinical Therapeutics – Clinical Trials; Clinical Therapeutics – Research; Diagnostics – Routine patient Tests; Diagnostics – Patient Screening; Diagnostics – Research; Diagnostics – Disease Biomarkers; Drug R&D – Discovery; Drug R&D – Drug Targets; Drug R&D – Preclinical studies; Drug R&D – ADME; Drug R&D – Toxicology; Drug R&D – Drug Metabolism; Drug R&D – Clinical Trials; Bioprocesses; Bacteriology; Cytology; Cytogenetics; Genomics; Metabolomics; Proteomics; Virology and any other.
End-user's main environment for the use of immunoassay, where the environments considered were Laboratory, Point of Care (POC), Blood Screening or any other.
The disease areas to which their immunoassay is used, where the diseases considered were Arthritis, Autoimmune Diseases, Bone Metabolism, Cancer, Cardiovascular, Central Nervous System, Dentistry, Dermatology, Endocrine, Gastrointestinal, Genito-urinary System, Haematology, Infections, Inflammation, Metabolic Disorders, Musculoskeletal Disorders, Nutrition, Obstetrics and Gynaecology, Ophthalmology, Pain, Psychiatry, Respiratory, Skin, any other or None.
The purpose of their immunoassay disease biomarker studies, where the purposes considered were Biomarker Discovery, Clinical – Research, Clinical – Trials, Diagnostics – Screening, Diagnostics – Research, Diagnostics – Routine tests, Disease research, Drug R&D – Clinical trials, Drug R&D – Drug targets, Drug R&D – Preclinical, Drug R&D – ADME, Toxicology, Treatment – Decisions, Treatment – Monitoring or any other.
The clinical utility of their immunoassay disease biomarker studies, where the options considered were Companion diagnostics, Disease prognosis, Disease stage or severity, Disease susceptibility or risk, Disease variability, Drug discovery, Drug therapy dose, Early detection of disease, Guiding treatment, Multiple utilities, Response to therapy, Safety or toxicity factors, Screening and monitoring, Therapy decision-making or other.
Organisation Types: Immunoassay end-user's organisation type, where the options were Clinic, Government Organisation, Hospital, Large International Company, Medium Sized Company, Research Institute, Small Company, Teaching Hospital, University, Veterinary Organisation or other.